(Q44198069)

30 November 2017

title

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma (English)

1 reference

30 November 2017

Sharon Gordon

1

1 reference

30 November 2017

Miep H Helfrich

2

1 reference

30 November 2017

Hamdi I A Sati

3

1 reference

30 November 2017

Michael Greaves

4

1 reference

30 November 2017

Stuart H Ralston

5

1 reference

30 November 2017

Dominic J Culligan

6

1 reference

30 November 2017

Richard L Soutar

7

1 reference

30 November 2017

Michael J Rogers

8

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

British Journal of Haematology

30 November 2017

published in

1 reference

30 November 2017

volume

119

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

475-483

1 reference

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Anti-myeloma activity of pamidronate in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Bisphosphonates--mechanisms of action in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Detection of myeloma cells in the peripheral blood by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

10.1046/J.1365-2141.2002.03824.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference